Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Samsrita LabsBOM:539267 +4.97%18 FCF Yield % is -16.41 as of Aug. 08, 2026. GuruFocus rates BOM:539267 with a GF Score™ of 18/100. The stock has 3 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Samsrita Labs ranks worse than 78.4% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Samsrita Labs's FCF Yield % or its related term are showing as below:
BOM:539267'
s FCF Yield % Range Over the Past 10 Years
Min: -17.59 Med: 0 Max: 0
Current: -16.41
BOM:539267's FCF Yield % is ranked worse than 78.4% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.14
vs BOM:539267: -16.41
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Samsrita Labs FCF Yield % Related Terms
Samsrita Labs FCF Yield % Historical Data
* Premium members only.
The historical data trend for Samsrita Labs's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:539267 vs TMO, DHR, IDXX: FCF Yield % Comparison
For the Diagnostics & Research subindustry, Samsrita Labs's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Samsrita Labs FCF Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Samsrita Labs's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Samsrita Labs's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Samsrita Labs (BOM:539267) has a FCF Yield % of -16.41 as of Aug. 08, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Samsrita Labs and its competitors. According to the industry distribution chart, Samsrita Labs ranks #167 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 78.4%.
Is Samsrita Labs' FCF Yield % too high?
Samsrita Labs' current FCF Yield % is -16.41. Based on the distribution chart, Samsrita Labs ranks #167 out of 213 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Samsrita Labs has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Samsrita Labs' FCF Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Samsrita Labs ranks #167 out of 213 companies for FCF Yield %. This places Samsrita Labs in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Diagnostics & Research company?
A good FCF Yield % depends on the Medical Diagnostics & Research industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Samsrita Labs and its competitors. Samsrita Labs's current FCF Yield % is -16.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Samsrita Labs stock overvalued right now?
Samsrita Labs (BOM:539267) has a current FCF Yield % of -16.41. The current FCF Yield % is -16.41. Samsrita Labs' overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Samsrita Labs (BOM:539267), the current FCF Yield % is -16.41 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Samsrita Labs Ltd is an India based diversified healthcare company. The company's operations include research and excellence in the areas of Stem cell research and development and therapy, New drug discovery, Diagnostics and Bio Lab, Pharmacy, Out-Patient Consultancy Division in name of ORIGIN HOSPITALS, and Research and Development in Biotechnology. It has one reportable segment namely, healthcare services including hospital, diagnostics, Pharma, and Biotechnology.
18GF Score
Get the complete analysis for BOM:539267
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:539267 has been successfully added to your 
